In oncogene-addicted cancer cells, metabolic reprogramming to OXPHOS was observed to be involved in the mechanism of chemoresistance towards targeted therapy with the EGFR inhibitor gefitinib and the BRAF inhibitor vemurafenib in vitro [36]. Here, BRAF is linked to cancer.